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Rearranged during transfection (RET), a receptor tyrosine
kinase that is activated by the glial cell line-derived neu-
rotrophic factor family ligands (GFLs), plays a crucial role in the
development and function of the nervous system and addition-
ally is required for kidney development and spermatogenesis.
RET encodes a transmembrane receptor that is 20 exons long
and produces two known protein isoforms differing in C-termi-
nal amino acid composition, referred to as RET9 and RET51.
Studies of human pheochromocytomas identified two addi-
tional novel transcripts involving the skippingof exon3or exons
3, 4, and 5 and are referred to as RETE3 and RETE345, respec-
tively. Here we report the presence of RetE3 and RetE345 in
zebrafish, mice, and rats and show that these transcripts are
dynamically expressed throughout development of the CNS,
peripheral nervous system, and kidneys.We further explore the
biochemical properties of these isoforms, demonstrating that,
like full-length RET, RETE3 and RETE345 are trafficked to the
cell surface, interact with all four GFR co-receptors, and have
the ability to heterodimerize with full-length RET. Signaling
experiments indicate that RETE3 is phosphorylated in a similar
manner to full-length RET. RETE345, in contrast, displays
higher baseline autophosphorylation, specifically on the cata-
lytic tyrosine, Tyr905, and also on one of the most important
signaling residues, Tyr1062. These data provide the first evidence
for a physiologic role of these isoforms inRETpathway function.
RET is a receptor tyrosine kinase that is critical for kidney
morphogenesis, spermatogenesis, and development of the
nervous system (1–4). RET is activated by a family of four
growth factors known as the glial cell line-derived neu-
rotrophic factor (GDNF)2 family ligands (GFLs), which
includes GDNF, neurturin, artemin, and persephin (1). Each
GFL binds to one of four cognate glycosylphosphatidylinosi-
tol-anchored co-receptors known as the GDNF family recep-
tor s (GFRs) (2, 5). The GFL-GFR complex binds to RET,
inducing RET dimerization and subsequent autophosphory-
lation on multiple tyrosine residues within the intracellular
tyrosine kinase domain. This enhances tyrosine kinase activ-
ity and initiates the association of adaptor proteins and
enzymes that trigger multiple second messenger cascades
(6).
The presence of two major Ret isoforms, RET9 and RET51,
has been extensively described in the literature, and a third
isoform, RET43, has also been observed in humans (7–9). Ret is
20 exons long, and Ret9 and Ret51 transcripts differ in alterna-
tive splicing of intron 19. Intron 19 in the Ret51 transcript is
excised properly, whereas, in the Ret9 transcript, the intron is
retained, changing the reading frame and inserting a premature
stop codon into the amino acid sequence. This creates a unique
nine-amino acid C-terminal sequence for RET9 and a unique
51-amino acid C-terminal sequence for RET51. Interestingly,
these two different isoforms displaymarked differences in their
degradation and function (7, 10, 11).
Three additional Ret transcripts have been reported in vari-
ous tumor sources as well as adult human tissues (12). These
novel transcripts are a product of exon skipping in the 5 region
of RET, which encodes for the extracellular domain of the pro-
tein. Skipping of exons 3 (RETE3) or exons 3, 4 and 5
(RETE345) gives rise to transcripts that encode for full-length
Ret proteins butwith deletions in the extracellular domain, spe-
cifically cadherin-like domain 1 (CLD1) or CLD1–3, respec-
tively. These deletions are hypothesized to change the extracel-
lular domain structure as well as binding to GFL-GFR
complexes and may impact the overall stability of the proteins.
The skipping of exons 3 and 4 results in a frameshift that cul-
minates in a premature stop. This protein encodes only a small
portion of the RET extracellular domain with no transmem-
brane or intracellular domain. Because this transcript is likely to
be subjected to nonsense-mediated decay, it is unlikely to be
involved in RET signal transduction.
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Here we show that RetE3 and RetE345 transcripts are
conserved in vertebrates and that the mRNA and proteins of
these splice variants are expressed throughout the nervous
system in mice. We also show that these isoforms are traf-
ficked to the cell surface and that both isoforms interact with
all four GFRs. Additionally, we find that RETE3 is phos-
phorylated to a similar level as full-length RET and is acti-
vated in a GDNF-dependent manner. However, RETE345
displays higher baseline autophosphorylation, specifically
on the catalytic tyrosine Tyr905, and also on an additional
signaling tyrosine, Tyr1062. Interestingly, RETE345 is not
activated in a GDNF-dependent manner. Taken together,
these isoforms may have unique and important unidentified
roles in the development and maintenance of the nervous
system and kidneys as well as in the pathophysiology of neu-
roendocrine gland diseases.
Results
Exons 3, 4, and 5 of Ret Are Not Highly Conserved, but RetE3
and RetE345 Transcripts Are Observed in Several Organisms—
It has been described previously that the intracellular domain of
RET, which contains a tyrosine kinase domain, is more highly
conserved than the extracellular domain (13). To better under-
stand the level of conservation of amino acids encoded by each
exon, we compared sequences from zebrafish (Danio rerio),
mouse (Mus musculus), rat (Rattus norvegicus), and human
(Homo sapiens). We found that the entire intracellular domain
was more than 75% conserved at the amino acid level. This was
not surprising because mutations in many of these highly con-
served regions give rise to loss of function (e.g. Hirschsprung
disease) or gain of function (e.g. multiple endocrine neoplasia
type 2A (MEN2A) and 2B (MEN2B)) phenotypes (Fig. 1A).
Interestingly, exons 3, 4, and 5 are less than 50% conserved
between these species. Although this lack of conservation is
suggestive that these regions of RET are not as functionally
important, it could also be interpreted as allowing for amino
acid flexibility between the different RET isoforms.
Our initial sequence analysis suggested that RetE3 and
RetE345 transcripts could be expressed in additional verte-
brates other than H. sapiens. These transcripts were originally
identified in human kidney and substantia nigra fetal tissues
(12). Sequence analysis demonstrated that exon skipping also
encodes potential full-length transcripts in zebrafish, mice, and
rats (Fig. 1A). To determine whether these novel transcripts
were expressed in these organisms, species-specific primers
were created to identify each of the Ret transcripts: full-length
Ret, RetE3, and RetE345. RT-PCR analysis identified the pres-
ence of RetE3 and RetE345 from 48 hours post fertilization
zebrafish embryos, E19.5 rat dorsal root ganglia, and E18.5
mouse spinal cord (Fig. 1B). Sequence analysis confirmed these
amplicons to be RetE3 and RetE345 (data not shown). This is
the first time these transcripts have been identified in verte-
brates other than H. sapiens. Taken together, these data indi-
cate that 5 exon skipping is conserved and results in the
expression of RetE3 and RetE345 transcripts.
Exon Skipping Creates Large Deletions in the Extracellular
Domain of RET—To understand the impact deletions in the
extracellular domain would have on RET, we analyzed the dele-
tions in terms of a CLD1–4 model derived from electron
microscopy and small angle x-ray scattering analyses (14). The
main consequence of deletion of exon 3 is the removal of half of
CLD1 (residues 113–150) and half of CLD2 (residues 154–
208). Each domain adopts a  sandwich cadherin fold com-
prised of two  sheets separated by numerous buried hydro-
phobic residues. Elimination of exon 3 removes one sheet from
CLD1 and several strands fromboth sheets of CLD2 (Fig. 1C).
Therefore, it is likely that both CLD domains are substantially
perturbed leaving strands without the cadherin fold structure
and exposing some hydrophobic residues. Exon 3 removal also
eliminates a highly constrained Cis-Pro loop (Cys137-Cys142)
unique to higher vertebrate RET sequences. The portion of
CLD1–2 removed coincides with regions stabilizing the clam
shell arrangement of CLD1–2 (15). This would result in a more
open and extended arrangement for the remaining parts of
CLD1 and CLD2 with much greater flexibility between the
domains. An odd number of cysteine residues (three in total)
are deleted by removing exon 3, including the Cys157-Cys197
disulfide. Cys166 is also removed, leaving its partner Cys243
unpaired but buried. The two unpaired cysteines, Cys87 and
Cys216, which constitute a known folding bottleneck in wild-
type RET, are left untouched. We expect RETE3 to be a less
stable transmembrane protein with a short half-life that retains
at least some ligand-binding properties.
For RETE345, removal of exons 3, 4, and 5 effectively elimi-
nates much of CLD1–3 but leaves CLD4-cysteine-rich domain
(CRD) intact (Fig. 1C). This region by itself was shown to be
insufficient to bind ligand but retains at least one important
binding epitope (i.e. necessary for ligand binding but not suffi-
cient) (14). Many receptor tyrosine kinases have extracellular
domains that have autoinhibitory functions in the absence of
ligand. Deletion of such regions can lead to autoactivation in a
ligand-independent manner. By analogy with these other sys-
tems, removal of CLD1–3 could leave a truncated form of RET
that would be constitutively activated in the absence of ligand
and likely would be unresponsive to the GFLs.
RetE3 and RetE345 Are Co-expressed in Several Tissues with
Ret throughout Development—To determine where and when
RetE3 andRetE345 transcripts are expressed andwhether their
expression levels change over time, we analyzed tissues in
which full-length Ret is expressed at several developmental
time points. Within the central nervous system, we analyzed
the brain, as signaling via Ret is important for the survival of
central noradrenergic neurons and dopaminergic neurons in
the ventral midbrain, as well as the spinal cord, where GDNF/
GFR1/Ret signaling is critical for axon guidance into the hind
limbs and survival of motor neurons (16–21). In the periph-
eral nervous system, we analyzed sensory neurons of the dorsal
root ganglia (DRG), where neurturin/GFR2/Ret signaling is
important for the survival and maintenance of mechanorecep-
tors during development (22, 23). Additionally, shortly after
birth, a subclass of nociceptors transition from being TrkA-
positive to expressing GFR1/Ret to support the development
and survival of nonpeptidergic nociceptors (24–26). Sympa-
thetic neurons of the superior cervical ganglia (SCG) were also
analyzed, as it has been well established that artemin/GFR3/
Ret signaling is necessary for proper sympathetic chain migra-
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tion and axon guidance during development (27–29). Last, the
kidney was analyzed because GDNF/GFR1/Ret signaling is
crucial for ureteric bud branching and morphogenesis of the
kidney (30–34). Using qPCR, we examined the relative expres-
sion of Ret, RetE3, and RetE345 in each of these tissues in mice
and found that theywere detected in all five tissues. The relative
expression of Ret, RetE3, and RetE345 was lower in the brain,
spinal cord, and kidney (Fig. 2A) compared with the DRG and
SCG (Fig. 2B). Interestingly, in the spinal cord, DRG, and SCG,
there was a significant increase of RetE3 expression at E19.5
that preceded a significant increase ofRet at P3. The expression
of all three transcripts was highest in the DRG, particularly at
E19.5 and P3, when the IB4 subpopulation of nociceptors is
emerging.
5 and 3 Alternative Splicing of Ret transcripts Are Not
Mutually Exclusive—Alternative splicing of intron 19 in Ret
allows for the translation of two isoforms of Ret, RET9 and
RET51. We sought to determine whether alternative splicing
could occur simultaneously, both 5 and 3 in Ret transcripts,
allowing for increased diversity of encoded RET proteins.
cDNA was isolated from E19.5 mouse DRGs, as we found this
tissue to have the highest relative expression of Ret, RetE3, and
RetE345 (Fig. 2B). Forward primers specific for each 5 splicing
event were paired with reverse primers that would detect either
Ret9 or Ret51 alternative splicing. Full-length Ret9 and Ret51
transcripts were detected, as expected, at 3.33 kb and 4.38 kb,
respectively. We observed RetE3 and RetE345 with intron 19
retention, thus encoding RetE3 and RetE345 transcripts with
FIGURE 1. Removal of exons 3 or 3, 4, and 5 of RET creates proteins with large deletions in the extracellular domain, and transcripts encoding these
receptors are expressed in multiple organisms. A, comparison of the amino acid sequences of RET between zebrafish, mice, rats, and humans was per-
formed, and the conservation within each exon is indicated by color. Interestingly, the amino acids encoded in exons 3, 4, and 5 are the least conserved.
Additionally, the impact of exon skipping on the extracellular domainwithin the protein is shown. B, RetE3 and RetE345 transcripts are detectable in zebrafish
(D. rerio), mice (M. musculus), and rats (R. norvegicus) by qPCR. Like human RETE3 and RETE345, alternative splicing of exon 3 or exons 3, 4, and 5 in these
vertebrates are predicted to encode full-length, transmembrane RET proteins with deletions in the extracellular domain. C, deleted regions are shown in red,
projected onto a structural model for RET cadherin domains 1–4 derived from PDB code 4UX8.
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amplicons of 3.05 kb and 2.61 kb, respectively. However, we
were only able to detect RetE345with a properly excised intron
19 at an amplicon size of 3.66 kb, encoding a Ret51E345 tran-
script. Although we were unable to detect a Ret51E3 transcript
(4.10 kb), this is likely due to the generally low expression levels
of RetE3.Taken together, these data indicate that the Ret locus
encodes for at least three previously unidentified transcripts
and at least five total Ret isoforms: Ret9, Ret9E3, Ret9E345,
Ret51, and Ret51E345.
RET Proteins of the SameMolecular Weight as RETE345 Are
Detected in Vivo—Although we can detect RetE3 and RetE345
mRNA transcripts, which are likely being processed for trans-
lation, we sought to detect the presence of these isoforms at the
protein level. Plasmids encoding humanRET51,RET51E3, and
RET51E345 were transfected into NIH/3T3 cells, and lysates
were run as size standards to aid in detectingRet isoforms of the
appropriate molecular weights from E18.5 mouse brain. The
molecular weight of native RET51 protein is 120 kDa, but
FIGURE2.RetE3andRetE345aredynamicallyexpressedthroughoutdevelopment,andRETproteinswithsimilarmolecularweightsasRETE345aredetect
invivo.A, expressionofRet,RetE3, andRetE345 inmousebrain (E15.5,E19.5,P3), spinalcord (E15.5,E19.5,P3,adult), andkidney (E15.5,E19.5,P3,adult)byqPCR is shown
as relative expression comparedwithactin.B, expressionofRet,RetE3, andRetE345 inmouse sympathetic (E19.5,P3,adult) andDRGsensoryneurons (E15.5, E19.5,P3,
adult)byqPCR isgraphedas inA.C, cDNAfromE19.5DRGswassynthesized frompoly(A)RNA,andRT-PCRwasperformedtodetermine thepresenceofRet transcripts
with both 5 and 3 alternative splicing. Ret9, Ret9E3, Ret9E345, Ret51, and Ret51E345 transcriptswere identified.D, E18.5mouse brainswere lysed, and immunopre-
cipitations (IP) forRET9orRET51wereperformed. Immunoblotting forRETdetectedfull-lengthRET9andRET51,asexpected.ThepresenceofRET9andRET51proteins
at the samemolecular weight as RETE345 suggested the existence of RET9E345 and RET51E345 isoforms.
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because of posttranslational modifications, specifically glyco-
sylation of the extracellular domain, RET51 has a molecular
weight of 180 kDa. The native molecular weights of RETE3
andRETE345 were predicted to be 109 kDa and 93 kDa, respec-
tively. In transfected cells, we consistently observe the mature,
processed proteins to have molecular weights of 150 kDa
(RETE3) and125 kDa (RETE345) (Fig. 2D).
Whole brains from Ret/ or Ret/ E18.5 littermate mice
were lysed and divided in two, and immunoprecipitations were
performed to isolate either RET9 or RET51 proteins. Although
the qPCR data suggested that Ret transcripts have an overall
lower relative expression in the brain compared with PNS tis-
sues, the brain was chosen for analysis because of the abundant
amount of protein that could be isolated. Ret/ mice were
used as a control to demonstrate the specificity of RET immu-
noblotting and to show the potential presence of RET proteins
at the samemolecular weight as RETE3 andRETE345. Because
we previously observed more highly expressed Ret9E345 and
Ret51E345 transcripts compared with those of RetE3, we
hypothesized that we would be most able to detect both
RET9E345 and RET51E345 proteins. By immunoblotting for
RET, we were able to detect full-length RET9 and RET51 pro-
teins, as expected (Fig. 2D). Additionally, we observed RET9
and RET51 bands with similar molecular weights to RETE345,
suggesting the presence of RET9E345 and RET51E345 proteins
in mouse brain (Fig. 2D). Because the antibodies used for
immunoprecipitations of RET9 and RET51 are to the C termi-
nus, and the RET antibody for immunoblotting is to the com-
mon N-terminal region, this RET protein is unlikely to be a
degradation product. However, we cannot exclude the possibil-
ity that this is an immature, non-glycosylated, full-length RET
protein.
RETE3 and RETE345 Are Trafficked to the Cell Surface—To
examine the biochemical properties of RETE3 and RETE345,
we transitioned to an in vitro system for these experiments.
Although RETE3 and RETE345 encode proteins that may be
capable of signaling, this does not guarantee that they will be
correctly trafficked to the cell surface for activation. To deter-
mine whether RETE3 and RETE345 are trafficked to the
plasmamembrane, NIH/3T3 cells were transfected with C-ter-
minally epitope-tagged Ret constructs that also contain an
IRES-GFP to serve as an indicator for transfected cells. Taking
advantage of a RET antibody specific for the extracellular
domain and using an HA antibody to label the C terminus of
RET, we were able to selectively visualize RET located on the
plasma membrane. Full-length RET was detected on the cell
surface of transfectedNIH/3T3 cells, as expected (Fig. 3K). Per-
meabilization revealed the C-terminal HA tag, confirming the
integrity of the plasma membrane (Fig. 3P). Similar to full-
length RET, both RETE3 and RETE345 were trafficked to the
cell surface, as determined with the extracellular RET antibody
in non-permeabilized cells (Fig. 3, S and A’). Transfection of
GFP alone showedno labelingwith theRET andHAantibodies,
regardless of permeabilization, confirming the specificity of our
immunostaining (Fig. 3, A–H). A cell surface biotinylation
experiment was performed as a secondary measure to confirm
these results, and we again observed trafficking of full-length
RET, RETE3, and RETE345 to the cell surface (data not
shown). Thus, RETE3 and RETE345 are trafficked properly to
the cell surface, where they can participate in GFL-mediated
activation.
RETE3 and RETE345 Bind to GFR1, GFR2, GFR3, and
GFR4—Previous structural analysis (Fig. 1C) suggested that
interactions between RETE3 and the GFRs may be unstable
and that RETE345would be unlikely to bind to the co-receptors
because of deletions of important binding residues inCLD1 and
CLD3. To confirm these results, we co-transfected HEK293T
cells with RETE3 or RETE345 and HA epitope-tagged GFR
constructs (HA::GFR1 (mouse),HA::GFR2 (rat),HA::GFR3
(mouse), and HA::GFR4 (chicken)). Immunoprecipitations
were performed using a stringent immunoprecipitation buffer
(modified radioimmune precipitation assay buffer) to eliminate
any weak, nonspecific interactions. Surprisingly, we found that
both RETE3 and RETE345 bind to each of the fourGFRs (Fig.
4). Co-transfection of the GFRs with TrkA, another receptor
tyrosine kinase, was performed as a negative control to show
selectivity of binding between the GFRs and RET (Fig. 4). As
expected, TrkA did not associate with any of the GFRs. There
were no apparent differences between the four different GFRs
in regard to the extent of their association with RETE3 and
RETE345, suggesting that these splice variants could poten-
tially be activated by all four GFLs (Fig. 4).
RETE3 and RETE345 Heterodimerize with Full-length
RET—In addition to being potential signaling molecules on
their own, we observed that these transcripts are normally
expressed in tissues where full-length RET is also expressed
(Fig. 2). Although these isoforms may be present in different
cells within these tissues, these observations raise the question
of whether RETE3 and RETE345 could heterodimerize with
full-length RET and affect its function. To test this possibility,
HEK293T cells were co-transfected with HA epitope-tagged
RET51 and untagged RETE3 or RETE345. Immunoprecipita-
tions were performed using an HA antibody to select for full-
length RET51 and determine whether the different isoforms
could interact with one another (Fig. 5A). In an additional
experiment, FLAG-tagged RET51E345 (FLAG:: RET51E345)
was co-transfected with RET51 and RET51E3, and immuno-
precipitations were performed using a FLAG antibody to select
for RET51E345 (Fig. 5B). We found that both RET51E3 and
RET51E345 associated with full-length RET51 and that
RET51E3 and RET51E345 could also bind to one another (Fig.
5). This is consistent with former experiments suggesting that
overexpression of RET proteins allows for ligand-independent
dimerization via the transmembrane domain (35).
RETE345 Has Increased Ligand-independent Activation
Compared with RET and RETE3—To determine levels of acti-
vation of RETE3 and RETE345, the basal phosphorylation of
tyrosine residues of the RET isoforms were compared with full-
length RET phosphorylation. Overexpression of the RET iso-
forms in vitro, either in the presence or absence of a GFR,
allows for ligand-independent dimerization and activation of
RET. The level of activation can be assessed by determining the
summated level of all of the phosphorylated tyrosines using a
pan-phosphotyrosine antibody, or individual tyrosine residues
can be analyzed using residue-specific RET phosphotyrosine
antibodies. We evaluated the level of total phosphotyrosine
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FIGURE 3. RETE3 and RETE345 are trafficked to the cell surface. NIH/3T3 cells were transfected with GFP (A–H), Ret51::HA (I–P), Ret51E3::HA (Q–X), or
Ret51E345::HA (Y–F’). Constructs for the RET51 isoforms were bicistronic, allowing for expression of GFP as an indicator for positive transfection, which was
encoded by an IRES-GFP following RET cDNA sequences. Cells were washed in 1 PBS and fixed briefly in 4% paraformaldehyde 24 h post-transfection. Cells
were thenblocked in immunofluorescenceblocking solutionwithorwithout TritonX-100 toallow for cellmembranepermeabilization. In theabsenceof Triton
X-100, antibodies specific for the RET extracellular domain were able to bind to RET51::HA (K), RET51E3::HA (S), and RET51E345::HA (A’). However, using an
antibody against theHAepitope thatwould detect the C terminus located intracellularly for RET51::HA (L), RET51E3::HA (T), and RET51E345::HA (B’) showedno
binding/fluorescence in the absence of Triton X-100. When immunofluorescence blocking solution with Triton X-100 was used, fluorescence was detected
using the anti-HA antibody for RET51::HA (P), RET51E3::HA (X), and RET51E345::HA (F’). These data show that RET51E3 and RET51E345 are trafficked to the cell
surface similarly as full-length RET51. Scale bars represent 20 m.
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(Tyr(P)) between the RET isoforms and individually evaluated
phosphorylation at two tyrosine residues of RET, Tyr905 and
Tyr1062. Tyrosine 905 in the RET kinase domain is an autocat-
alytic tyrosine that is conserved in many receptor tyrosine
kinases and is a binding site for GRB7 and GRB10 (36–38).
Additionally, mutation of tyrosine 905 to phenylalanine
(Y905F) impairs the kinase activity of RET (39). Tyrosine 1062
is a binding site for SHC, Dok4/5, IRS-1, and FRS-2 when phos-
phorylated and is a binding site for Enigma in a phosphoryla-
tion-independent manner (36, 40–47). Interaction between
Tyr1062 and these adaptor proteins leads to activation of the
Ras/ERK and PI3K/AKT pathways (41, 42, 45, 46, 48).
To evaluateRETphosphorylation,NIH/3T3 cellswere trans-
fected with RET51, RET51E3, or RET51E345 constructs in the
presence or absence ofGFR1, and the total levels of phosphor-
ylatedRETor the level of phosphorylation at Tyr905 andTyr1062
were assessed. To analyze total Tyr(P) levels of RET, immuno-
precipitations of RET51were performed, followed by immuno-
FIGURE 4. RETE3 and RETE345 bind to GFR1, GFR2, GFR3, and GFR4. RET51, RET51E3, and RET51E345 were co-transfected with HA epitope-tagged
GFR1 (A),GFR2 (B),GFR3 (C), orGFR4 (D). Immunoprecipitations (IP)wereperformedusing anHAantibody to select forGFRs. Immunoblotting (IB) for RET
showed interaction of RET51E3 and RET51E345 with all four GFRproteins. Co-transfection of HA::GFR1, HA::GFR2, HA::GFR3, or HA::GFR4with TrkAwas
performed as a negative control, and, as expected, TrkA did not associate with any of the GFRs.
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blotting for Tyr(P) (Fig. 6A). An increase in the level of
RETE345 phosphorylation compared with full-length RET was
observed, but this was not statistically significant (p 0.0837).
We did detect, however, a significant increase in the Tyr(P)
level of RETE345 co-expressed with GFR1 compared with
full-length RET co-expressed with GFR1 (p  0.0366). The
phosphorylation of RETE3 co-expressed with GFR1 or
expressed alone was not significantly different from full-length
Ret (p 0.6231).
To determine levels of Tyr(P)905 and Tyr(P)1062, pre-immu-
noprecipitation lysates were collected from samples in the pre-
vious experiments, and immunoblotting was performed using
antibodies specific for these two phosphorylated tyrosine resi-
dues (Fig. 6B). Levels of Tyr(P)905 and Tyr(P)1062 were signifi-
cantly elevated for RETE345 compared with RET (p  0.0439
and p  0.0411, respectively) and also for RETE345 co-ex-
pressed with GFR1 compared with full-length RET co-ex-
pressed with GFR1 (p 0.0106 and p 0.0096, respectively).
However, levels ofTyr(P)905 andTyr(P)1062were unchanged for
RETE3 compared with RET and also for RETE3 co-expressed
with GFR1 compared with full-length RET co-expressed with
GFR1. Taken together, these data suggest that RETE3 has a
similar activation level as full-length RET, whereas RETE345
has an elevated activation level compared with RET in a ligand-
independent manner. Additionally, the lower total phospho-
tyrosine level for RETE345 compared with Tyr(P)905 and
Tyr(P)1062 suggests that one or more of the other tyrosine res-
idues in RET is not phosphorylated as highly as Tyr905 and
Tyr1062 compared with full-length RET.
Because we consistently observed an increased level of tyro-
sine phosphorylation of the RETE345 isoform compared with
full-length RET, we wondered whether this level of receptor
activation was similar to oncogenic RET mutations, partic-
ularly those found in MEN2. Human RET point mutations
known to be causal for either MEN2A orMEN2B were intro-
duced into the RET51 expression plasmid, specifically C634R
(RET51MEN2A) andM918T (RET51MEN2B).NIH/3T3 cellswere
transfected with RET51, RET51E3, RET51E345, RET51MEN2A,
or RET51MEN2B constructs. Immunoprecipitations for RET51
were performed to isolate RET proteins, followed by immuno-
blotting for Tyr(P) as described previously. We observed a sig-
nificant increase in the level of phosphorylation of both
RETMEN2A and RETMEN2B oncogenic proteins compared with
full-length RET (p 0.0282 and p 0.0097, respectively) (Fig.
6F). The levels of phosphorylation of RETMEN2A andRETMEN2B
comparedwith RETE345 showed no significant difference (p
0.4898 and p  0.1712, respectively). These data indicate that
the RETE345 isoform is phosphorylated at similar levels as
oncogenic RET mutations.
RETE3 Is Activated in a GDNF-dependent Manner but
RETE345 Is Not—Although differences are observed in the
level of ligand-independent activation for RETE3 and
RETE345, we wondered whether these two receptors could be
activated in a GDNF-dependent manner. To evaluate this,
Neuro2A cells were co-transfected with HA epitope-tagged
RET51, RET51E3, or RET51E345 and with untagged GFR1.
Twenty-four hours post-transfection, the culture medium was
removed, and cells were stimulated with 200 ng/ml recombi-
nant mouse GDNF for 30 min. Cells were detergent-extracted,
and immunoprecipitations for HA were performed to isolate
the exogenous RET isoforms. Immunoblotting for GFR1 was
performed to determine the level of GDNF-dependent associ-
ation of GFR1 to RET (Fig. 7A). For our positive control,
where GFR1 and RET51 were co-expressed, we observed a
significantGDNF-dependent association of these proteins after
30 min of stimulation (p 0.0373) (Fig. 7B). Under conditions
FIGURE 5. RETE3 and RETE345 can heterodimerize with full-length RET. A, HA epitope tagged RET51 (RET51::HA) was co-transfected with untagged
RET51E3orRET51E345 inHEK293T cells. Immunoprecipitations (IP)wereperformedwith anHAantibody to select for RET51::HA. Immunoblotting (IB) for RET51
showed co-immunoprecipitation of RET51E3 and RET51E345 with full-length RET51. B, a similar experiment was performed using FLAG epitope tagged
RET51E345 (FLAG:: RET51E345). Immunoprecipitationswith ananti-FLAGantibody selected for FLAG:: RET51E345. Immunoblotting for RET51demonstrated the
association of RET51 and RET51E3 with FLAG:: RET51E345. Co-transfections with TrkA were performed for both experiments as a negative control, and
immunoblotting for TrkA showed no binding with either RET51::HA or FLAG::RET51E345, as expected.
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where GFR1 and RET51E3 or RET51E345 were co-ex-
pressed, we observed a trend of GDNF-dependent association
of GFR1 to both RET isoforms, but this ligand-dependent
interaction was not statistically significant (p 0.1750 and p
0.3269, respectively).
To determine whether the RET isoforms were activated in a
GDNF-dependent manner, immunoblotting for poly-ubiquitin
was performed. We have shown previously that, upon ligand
activation and autophosphorylation, RET is rapidly poly-ubiq-
uitinated and targeted for degradation (49). Because ectopic
FIGURE 6. RETE345 displays increased ligand-independent activation compared with full-length RET. A, RET51 was co-transfected with HA
epitope-tagged GFR1 in NIH/3T3 cells. Immunoprecipitations (IP) were performed with a RET51 antibody to select for the RET isoforms. Immunoblot-
ting (IB) for phospho-tyrosine and RET was performed, and integrated density values were calculated for each. B, preimmunoprecipitation lysates from
the previous experiment were subjected to SDS-PAGE, and Western blotting was performed to determine the levels of residue-specific tyrosine
phosphorylation of RET. Immunoblotting was performed for phospho-RET (Tyr905), phospho-RET (Tyr1062), and RET, and integrated density values
were calculated for each. Ratios of phospho-RET/RET (C), phospho-RET (Tyr905)/RET (D), and phospho-RET (Tyr1062)/RET (E) are reported, with values
normalized to RET51. F, expression plasmids encoding oncogenic RET proteins, RET51MEN2A and RET51MEN2B, were transfected into NIH/3T3 cells, and
integrated density values were calculated and analyzed for phospho-RET/RET for all RET isoforms. *, p 	 0.05; **, p 	 0.01; n.s., not signif-
icant.
Novel RET Isoforms Differentially Regulate RET Signaling
JULY 29, 2016•VOLUME 291•NUMBER 31 JOURNAL OF BIOLOGICAL CHEMISTRY 16257
 at Francis Crick Institute on O
ctober 5, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
expression of RET results in high levels of autophosphorylation
in the absence of ligand, we were not able to use phosphoty-
rosine immunoblotting as a measure of RET activation upon
GDNF stimulation. We observed a significant increase in poly-
ubiquitinated RET51 (p  0.0370) following GDNF stimula-
tion, as expected, and also observed a significant increase in
poly-ubiquitinated RET51E3 (p 0.0493), suggesting that this
isoform is activated in a GDNF-dependent manner. Interest-
ingly, we did not observe a difference in the level of poly-ubiq-
uitinated RET51E345 following GDNF stimulation (p 
0.0696). These data suggest that, like full-length RET, RETE3 is
activated in a GDNF-dependent manner but RETE345 is not.
Discussion
Alternative splicing of precursor mRNA is one of many pro-
cesses that mediates gene regulation in metazoans, and the fre-
quency of alternative splicing increases with species complexity
(50, 51). For example, of the 25,000 genes encoded by the
human genome, 95% produce transcripts that are alterna-
tively spliced (50, 51). By expanding the proteome through the
synthesis of various protein isoforms, alternative splicing allows
for increased protein diversity, with isoforms performing dif-
ferent biological functions.
Here we provide evidence for two alternative splicing events
in Ret that, in combination with Ret9 or Ret51 alternative splic-
ing, give rise to at least fiveRet transcripts (Fig. 2C). The splicing
events for RETE3 and RETE345 have only been described pre-
viously in human tissues (12). Because an additional Ret tran-
script, RET43, is only expressed in humans, we examined the
expression of RETE3 and RETE345 in additional vertebrate
tissues to determine whether these might also be human-spe-
cific transcripts (8, 52). To this end, we discovered that RETE3
and RETE345 are not human-specific RET transcripts but are
also expressed in normal developing tissues of zebrafish, mice,
and rats (Fig. 1C). Functionally important transcripts are tran-
scriptionally conserved between species, arguing that RETE3
and RETE345 have physiologically important functions.
Analysis of an experimentally validated structural model for
the RET cadherin-like domains 1–4 was made to evaluate the
FIGURE 7.RETE3 is activated in aGDNF-dependentmanner but RETE345 is not.A, HA epitope-tagged RET constructswere co-transfectedwithGFR1 into
Neuro2A cells. Twenty-four hours post-transfection, themediumwas removed, and freshmediumwas added to cells containing 200 ng/ml GDNF. Cells were
stimulated for 30 min, and immunoprecipitations (IP) were performed from lysates with an HA antibody to selectively pull down the RET isoforms. Immuno-
blotting (IB) for GFR1 and RET was performed, and integrated density values were calculated for each. B, quantification the of GFR1/RET ratios. C, immuno-
blotting for poly-ubiquitin was performed, and integrated density values were calculated for poly-ubiquitinated RET and total RET. D, quantification of
poly-ubiquitinated RET/RET ratios.n.s., not significant.AU is arbitrary units.NoTx indicates cells thatwere not stimulatedwithGDNF.Asterisks indicatep	 0.05.
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consequence of exon deletions of RET alternative splicing on
the ligand binding and activation characteristics of RETE3 and
RETE345 (Fig. 1B). Previous experiments indicate that the
GDNF-GFR1 complex binds directly to CLD4 and the cys-
teine-rich domain (53). This suggested that both RETE3 and
RETE345 should be able to bind to theGDNF-GFR1 complex,
and indeed this interaction was observed not only for GFR1
but also for GFR2, GFR3, and GFR4 (Fig. 4). It should be
noted that, in our experiments, the chicken GFR4 construct
contained all three cysteine-rich domains, unlike mammalian
GFR4, which lacks domain 1. Although it was originally
thought that CLD1–3 of RET was involved in direct binding
from results obtained through mutagenesis studies, a direct
interaction between CLD1–3 and the GDNF-GFR1 complex
has not been observed (53, 54). Instead, it has been proposed
that CLD1–3 contributes to the stability of the tertiary struc-
ture of the GDNF-GFR1-RET complex by forming a second-
ary dimerization site to trap the GDNF-GFR1 binary complex
(14). These studies predict that RETE3, which forms a fused
CLD1-CLD2 region, likely gives rise to a less stable tertiary
GDNF-GFR1-RET complex compared with full-length RET.
This may result in a receptor variant with differential ligand
binding specificities. FGF receptors are a subfamily of four
receptor tyrosine kinases that are receptors for FGFs, of which
there are 18 ligands (55). Alternative splicing of the FGF recep-
tors in the region coding for the extracellular ligand-binding
domain of the receptors allows for differential ligand binding. It
is possible that the alternative splicing responsible for RETE3
similarly modifies GFL-GFR affinity. Alternatively, the trun-
cated extracellular domain of RETE3 may cause alterations in
the conformational changes that occur upon GFL-GFR bind-
ing that induces receptor autophosphorylation. This would
cause different autophosphorylation kinetics in RETE3 com-
pared with full-length RET and, therefore, differential activa-
tion of downstream second messenger cascades. Biochemical
experiments using an in vitro system that allows for the moni-
toring of autophosphorylation upon direct ligand activation of
RETE3 or full-length RET in isolation will be necessary to dis-
tinguish between these possibilities.
The large deletion in the extracellular domain of RETE345,
including the Ca2 binding domain, which is important for
RET folding and ligand-dependent signaling, is predicted to
have dramatic effects on RETE345 activation. Indeed, it is likely
that RETE345 functions as a constitutively active form of RET,
consistentwith themechanistic data shown inFig. 6.Autophos-
phorylation of RETE345 is increased comparedwith full-length
RET in the presence and absence of GFR1 in vitro (Fig. 6B).
Constitutively active receptor tyrosine kinases have not been
found in normal tissues and usually arise from germline and
somatic mutations, where they are most commonly found to
cause neoplasia. Activatingmutations in RET have been shown
to be responsible for multiple endocrine neoplasia, type 2,
including neoplasias such as medullary thyroid carcinoma and
pheochromocytomas (56). Unlike other constitutively active
forms of RET, RETE345 may be posttranscriptionally or trans-
lationally regulated in vivo in amanner that is not recapitulated
in the in vitro system used here. In this way, the signaling of
RETE345 may be under tight regulation for this isoform to per-
form specific functions in vivo.
To interrogate the functions of RETE3 and RETE345 in pri-
mary neurons and tissues, we attempted to generate isoform-
specific antibodies. Likewise, we also tried to create siRNAs to
selectively knock downRetE3 andRetE345 transcripts.Neither
of these experimental approaches were successful at targeting
RETE3 and RETE345 without also affecting full-length RET.
Therefore, to determine the physiologic functions of RETE3
and RETE345, a transgenic approach in a vertebrate will be
required to selectively remove these individual transcripts. This
could be accomplished by deleting specific introns and fusing
the flanking exons in-frame to inhibit exon skipping (e.g.
remove intron 3 and fuse exons 2 and 3 together to inhibit
alternative splicing for RetE3). How this approach would affect
RET expression and other splicing events, however, is
unknown. In addition, because of the invariably coincident
expression ofRetE3 andRetE345 in the same tissues asRet, it is
possible that full-length RETmay compensate for the functions
of RETE3 and RETE345. As an alternative approach, produc-
tion of knockin animals in which only RetE3 or RetE3 is
expressedwould determinewhether these isoforms are capable
of supporting the normal development of the nervous system
and kidneys.
Last, to gain a mechanistic understanding of the factors
responsible for the alternative splicing of Ret, it would be
interesting to explore RNA motifs encoding exon splicing
enhancers within the locus that impact the formation of
RetE3 and RetE345. Understanding the spliceosome machin-
ery involved in this process may help us understand why the
expression of these transcripts are elevated in tumors, such as in
pheochromocytomas (12). Overall, it may be necessary to
return to a disease model, such as neuroendocrine gland
tumors, where these RET transcripts were originally identified
and use the pathobiology to understand the signaling capacities
of RETE3 and RETE345 to identify their functions in normal
development.
Experimental Procedures
Molecular Modeling—This analysis was performed as
described previously (14). Models of cadherin-like domains
1–4 were taken from PDB code 4UX8, defined by a combina-
tion of EM and small angle x-ray scattering analyses. The figure
was made using PyMOL software (Schrödinger).
RNA Isolation, RT-PCR, and qPCR—Total RNA was isolated
from zebrafish, mouse, or rat tissues using TRIzol reagent
(Thermo Fisher Scientific) according to the instructions of the
manufacturer. cDNA synthesis was performed from 1 g of
total RNA to generate poly(A) first-strand cDNA using the
SuperScript III First-Strand Synthesis System for RT-PCR kit
(Life Technologies). For RT-PCR reactions with amplicons of
less than 200 bp, GoTaqGreenMasterMix (Promega) and spe-
cies-specific oligonucleotide primers forRet,Ret3, andRet345
were used. RT-PCR reactions with amplicons greater than 200
bp were performed using the Phusion high-fidelity DNA poly-
merase kit (New England Biolabs) following the instructions of
the manufacturer. qPCR was performed using FastStart Uni-
versal SYBR Green Master Mix (Roche) and run on a Quant-
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Studio 6 Flex real-time PCR system (Thermo Fisher Scientific).
Quantitative analyses were performed by calculating the Ct
(Ct of transcript divided by Ct of the housekeeping gene actin)
for each gene analyzed and transforming that value to log2.
These values are reported as the relative expression.
Primer Sequences—The primers used for this study were as
follows: ZF.RetFL.F, 5-TCG TAG TTT ACG CAG CGG CTC
A-3; ZF.RetFL.R, 5-TCG CGA TTT TCA GTG ATG TG-3;
ZF.Ret3.F, 5-CAGTAGTTTACGATCTTCTGTACCG-3;
ZF.Ret3.R, 5-TTC AGT GTC AGT CCC GTT GA-3;
ZF.Ret345.F, 5-CAG TAG TTT ACA GCT GAA ACT CAG
TC-3; ZF.Ret345.R, 5-TGA CAT TGG AGA AGC GAA
TG-3; Mouse.RetFL.F, 5-AGC ATC CGC AAT GGT GGT
TT-3; Mouse.RetFL.R, 5-TGT TCT CCC TGA CTC GGA
AG-3; Mouse.Ret3.F, 5-AGC ATC CGC AGG GAT AGT
CT-3; Mouse.Ret3.R, 5-ACA CTG TCA CTG GGA AGG
AC-3; Mouse.Ret345.F, 5-AGC ATC CGC AAG CTG ATT
CT-3; Mouse.Ret345.R, 5-TTC ACT GGG AAG GAG TAG
GC-3; Rat.RetFL.F, 5-AGC ATC CGC AAT GGC GGC
TT-3; Rat.RetFL.R, 5-TAG CAT GCG GAA CTG GTA
GA-3; Rat.Ret3.F, 5-AGCATCCGCAGGGACGGTCT-3;
Rat.Ret3.R, 5-CCG CTT AAA CTC CAC CAC AG-3;
Rat.Ret345.F, 5-AGC ATC CGC AAG CTG GTT CT-3;
Rat.Ret345.R, 5-TAG GCC ATG GGT AGG TTC AG-3;
Mouse.Ret9.R, 5-ATT TAC TGT CCA TTG CAA GGC-3;
and Mouse.Ret51.R, 5-CCT ATC AGT GCT TTA AGT
CTG-3.
Mice—Wild-type C57BL/6J mice were purchased from The
Jackson Laboratories (Bar Harbor,ME). Ret/mice have been
described previously and were maintained in a mixed genetic
background (57). For timed matings, noon of the day on which
a vaginal plug was detected was considered E0.5. All housing
and procedures performed on mice were approved by the Uni-
versity of Michigan Animal Care and Use Committee.
Detergent Extraction and Preclearing of Whole Tissues—Tis-
sues were harvested, placed in a 2-ml tubewith 250l of immu-
noprecipitation buffer lackingNonidet P-40 (TBS (pH7.4), 10%
glycerol, 500 M sodium vanadate, and protease inhibitors)
along with a steel grinding ball (5mm, 69989, Qiagen, Valencia,
CA) and mechanically homogenized using a TissueLyzer II
(Qiagen) for 2 min at a frequency of 20 Hz. Following this, 250
l of 2% Nonidet P-40-containing immunoprecipitation buffer
was added to homogenates and incubated for 1 h at 4 °C under
gentle agitation. Homogenates were then centrifuged for 10
min at 16,000  g and subjected to an initial preclearing step
with protein A and protein G alone at 4 °C for 2 h under gentle
agitation. A second preclearing step was performed with pro-
tein A, protein G, and a species-matched nonspecific control
IgG for 2 h under gentle agitation.
Immunoprecipitations and Immunoblotting—Plates were
placed on ice, gently washed twice with 1 PBS (pH 7.4), and
lysed with modified radioimmune precipitation assay buffer
(TBS (pH 7.4), 10% glycerol, 1% Triton X-100, 0.1% SDS, 500
M sodium vanadate, and protease inhibitors). Proteins were
immunoprecipitated using anti-RET9 (goat, Santa Cruz Bio-
technology), anti-RET51 (goat, Santa Cruz Biotechnology),
anti-HA (mouse, Millipore), or anti-FLAG (rabbit, Cell Signal-
ing Technology) selective antibodies. Immunoprecipitates
were subjected to SDS-PAGE, followed by electroblotting onto
PVDF membranes (Immobilon P, Millipore). Immunoblotting
was performed on blots using antibodies selective for RET
(1:500, goat, R&D Systems), HA (1:5000, rabbit, Cell Signaling
Technology), Trk (1:1000, rabbit, Santa Cruz Biotechnology),
phospho-tyrosine (1:1000, mouse, Millipore), phospho-RET
(Tyr905) (1:500, rabbit), phospho-RET (Tyr1062, 1:500, rabbit),
GFR1 (1:500, goat, R&D Systems), or poly-ubiquitin (1:500,
mouse, Enzo Life Sciences). Phospho-RET (Tyr905) and phos-
pho-RET (Tyr1062) have been described previously (58). Lysates
collected prior to immunoprecipitations served as loading con-
trols to assess protein expression levels and were also subjected
to immunoblotting for actin (1:1000, goat, Santa Cruz Biotech-
nology). Each biochemical experiment was performed three to
four times with similar results.
Mammalian Cell Culture and Transfections—NIH/3T3
(ATCC), HEK293T (ATCC), and Neuro2A cells (ATCC) were
maintained at 37 °Cwith 5%CO2 inDMEMsupplementedwith
FBS (10% by volume) and a penicillin/streptomycin/glutamine
mixture. Cells were plated into 6-well tissue culture plates and
allowed to proliferate until cells were 70% confluent. Transfec-
tions of cells were performedusing Lipofectamine 2000 accord-
ing to the instructions of the manufacturer (Invitrogen). For
experiments testing the interaction of proteins, a total of 4g of
plasmid DNA was added per well using a GFP plasmid as a
control for transfecting equal amounts of DNA. For in vitro
ligand-independent activation experiments, 2 g of
HA::GFR1 and 1 g of one of the RET constructs were trans-
fected for a total of 3 g of DNA per condition, with a GFP
plasmid used as a control for transfecting equal amounts of
DNA. RET51E3 and RET51E345 constructs were subcloned
from RET51 constructs into pcDNA3.1 (Thermo Fisher Scien-
tific). A Ret51 construct encoding mouse RET51 fused at the C
terminus with an HA epitope tag (RET51::HA) was acquired
from Dr. Ben Allen. This plasmid was subcloned to create sim-
ilarly tagged Ret51E3 and Ret51E345 constructs, which were
subcloned into pLentilox-IRES-GFP (University of Michigan
Vector Core). For in vitro ligand-dependent activation experi-
ments, 3 g of HA epitope-tagged Ret51, Ret51E3, or
Ret51E345 was co-transfected with 3 g of untagged GFR1.
Twenty-four hours post-transfection, the medium was aspi-
rated, and cells were treated with 200 ng/ml recombinant
mouse GDNF (Peprotech) in fresh cell culture medium for 30
min. TheHA::GFR1 (mouse) plasmidwas generously donated
by Dr. Ben Allen. The HA::GFR2 (rat), HA::GFR3 (mouse),
and HA::GFR4 (chicken) plasmids were generously donated
by Dr. Carlos Ibáñez. The TrkA (rat) plasmid was generously
donated by Dr. Christin Carter-Su. Constructs encoding
human RET51 harboring MEN2A (C634R) and MEN2B
(M918T) point mutations in RET were created using the
QuikChange II XL site-directed mutagenesis kit (Agilent).
Quantification of Immunoblots—Scanned images of x-ray
films were imported into ImageJ (National Institutes of Health)
and processed using the gel analysis tool. Integrated density
values obtained from immunoblotting were reported as
mean 
 S.E. with arbitrary units on the vertical axis. Values
were normalized to the level of RET51 phosphorylation in each
experiment. Statistical analyses were performed using
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Student’s t test for each experiment, and all biochemical exper-
iments were performed at least three times with similar results.
Immunocytochemistry—Transfected cells that were plated
on glass coverslips were fixed for 8 min in 4% paraformalde-
hyde. Cells were washed twice in 1 PBS and briefly blocked in
immunofluorescence blocking solution (3% BSA and 1% nor-
mal donkey serum in 1 PBS (pH 7.4)) with or without 0.1%
Triton X-100. Primary antibodies were diluted in blocking
buffer (RET (1:50, goat, R&D Systems), HA (1:1000, mouse,
Millipore)), and slides were incubated at 4 °C overnight. Cells
were washed twice with 1 PBS and then incubated at room
temperature for 1 h with secondary antibodies (donkey anti-
mouse Alexa Fluor 633 (Thermo Fisher Scientific), donkey
anti-goat 543 (Biotium)) diluted in blocking solution. Last, cells
were washed three times in 1 PBS and mounted with DAPI
Fluoromount-G (Southern Biotech). Cells were imaged using a
Zeiss Axiovert 200 M epifluorescence microscope with a 40
objective.
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